retatrutide
AssetAlso LY3437943, TRIUMPH-2
Activates GLP-1, GIP and glucagon receptors to regulate appetite, glucose metabolism and energy expenditure.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 15
- Indications
- 19
- Trials
- 2
- Developers
Indications
15Atherosclerotic cardiovascular disease
Phase 3, Active not recruiting, NCT06383390, clinicaltrials.gov, 7 Oct 2026
Cardiovascular disease
Phase 3, Completed, NCT05882045, clinicaltrials.gov, 7 Oct 2026
Chronic kidney disease
Phase 3, Active not recruiting, NCT06383390, clinicaltrials.gov, 7 Oct 2026
12 more
In the full profile
- Targets and what it contains6
- Owner and partners2
- Trials19
- Evidence for its targets7
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.